Nuvectis Pharma Inc

NVCT remains in a Stage 2 advancing phase with strong medium-term bullish bias supported by rising trend and an active Parabola pattern. However, extreme overbought conditions and price extended above EMAs weaken near-term execution readiness. As such, bullish engagement is deferred—stalking for a pullback into rising EMAs before participation.

• ↑Haisco agreement delivers $40M upfront, up to $1.421B in milestones.
• ↑NXP100 and NXP200 target treatment-resistant cancers with high unmet demand.
• ↓Negative earnings yield and extreme profitability deficits challenge sustainability.